Study on the efficacy and safety of Metformin hydrochloride enteric-coated capsules in patients with type 2 diabetes mellitus
10.3969/j.issn.1006-6187.2025.03.010
- VernacularTitle:盐酸二甲双胍肠溶胶囊治疗2型糖尿病有效性与安全性的研究
- Author:
Yiming WU
1
;
Jian ZHANG
;
Nan GU
;
Qijuan DONG
;
Ruiyun LIU
;
Hong ZHANG
;
Haixia LIU
;
Yongcai ZHAO
;
Lin CHENG
;
Lianshan PU
;
Fang BIAN
;
Gang HE
;
Quanmin LI
;
Wei DU
;
Zhaoling WANG
;
Wei XU
;
Liyong ZHONG
;
Xiaohui GUO
Author Information
1. 100034 北京大学第一医院内分泌科
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 2;
Metformin hydrochloride;
Non-inferiority trial
- From:
Chinese Journal of Diabetes
2025;33(3):210-214
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of enteric-coated metformin hydrochloride capsules(Junlida?)in patients with T2DM and poor glycemic control under lifestyle interventions.Methods In this study,419 patients with T2DM were recruited from 15 research centers from July 2020 to March 2022,and randomly divided into observation(Obs)group(n=209)and control group(Con,n=210)using a multicenter,randomized,double-blind,non-inferiority trial design.Patients in the Obs group were treated with enteric-coated Metformin hydrochloride capsules(Junlida?),and patients in the Con group were treated with Metformin hydrochloride tablets(Glucophage?).The optimal effective dose of 2 g/d was achieved within 4 weeks,and the reasonable dose was maintained until the end of treatment.The treatment period was 24 weeks.HbA1c and its compliance rate,FPG,and body weight were compared between the two groups in full analysis set(FAS)and protocol set(PPS).Safety and adverse events(AE)were evaluated in safety set(SS).Results A total of 414 participants were randomized(207 cases in Obs group and 207 cases in Con group).414 cases in FAS population(207 cases in Obs group and 207 cases in Con group),and 328 cases in PPS population(164 cases in Obs group and 164 cases in Con group),and 414 cases in SS population(207 cases in Obs group and 207 cases in Con group).After treatment,HbA1c,FPG and body weight were lower in both groups(P<0.05)in FAS and PPS.HbA1c compliance rate was not significantly different between the two groups in FAS and PPS(P>0.05).The results of non-inferiority test showed that the lower limit was>-0.4%in both FAS(-0.154,95%CI-0.384～0.069)and PPS(-0.139,95%CI-0.390～0.112),and the Obs group reached non-inferiority end point.The achievement rate,compliance rate,safety index and incidence of AE were not significantly different between the two groups(P>0.05).Conclusions Junlida? demonstrated non-inferiority to Glucophage? in glycemic control and can be safely and effectively used in patients with diabetes.
